New Four-in-One antibody takes on tough blood cancers

NCT ID NCT05104775

Ongoing Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 23 times

Summary

This early-stage study tests a new drug called GNC-035 in 33 adults with blood cancers that have come back or stopped responding to treatment. The main goal is to check safety and find the right dose. The drug is a special antibody designed to attack cancer cells in multiple ways.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Affiliated Hospital of Guizhou Medical University

Guiyang, Guizhou, China
Guangzhou First People's Hospital

Guangzhou, Guangdong, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, 200025, China
Shengjing Hospital of China Medical University

Shenyang, Liaoning, China
The Fourth Hospital of Hebei Medical University

Shijiazhuang, Hebei, China
The Second People's Hospital of Yibin

Yibin, Sichuang, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, China

Conditions

Explore the condition pages connected to this study.

HEMATOLOGIC MALIGNANCIES